• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta ‐analysis
ConclusionsUse of NOACs compared to VKAs significantly reduced the risk of bleeding in patients with AF ablation. Similarly, the risk of bleeding was lower with uninterrupted NOACs than with uninterrupted VKAs, and with interrupted NOACs than with interrupted VKAs. The rate of thromboembolic complications was extremely low in both study groups without any differences.
Source: Cardiovascular Therapeutics - September 12, 2018 Category: Cardiology Authors: Zhen Ge, Michela Faggioni, Usman Baber, Samantha Sartori, Sabato Sorrentino, Serdar Farhan, Jaya Chandrasekhar, Birgit Vogel, Abdul Qadeer, Jonathan Halperin, Vivek Reddy, Srinivas Dukkipati, George Dangas, Roxana Mehran Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Warfarin prescription in patients with nonvalvular atrial fibrillation and one non –gender‐related risk factor (CHA2DS2VASc 1 or 2): A treatment dilemma
ConclusionWe found an elevated risk of major bleeding and intracranial hemorrhage in NVAF individuals treated with warfarin with 1 NGR risk factor for stroke. These data call for caution when treating with warfarin these individuals.
Source: Cardiovascular Therapeutics - November 11, 2017 Category: Cardiology Authors: Gentian Denas, Giacomo Zoppellaro, Seena Padayattil Jose, Emilia Antonucci, Francesco Marongiu, Daniela Poli, Sophie Testa, Armando Tripodi, Gualtiero Palareti, Vittorio Pengo Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Warfarin prescription in patients with non ‐valvular atrial fibrillation and one non‐gender related risk factor (CHA2DS2VASc 1 or 2): a treatment dilemma
ConclusionWe found an elevated risk of major bleeding and intracranial haemorrhage in AF individuals treated with warfarin with 1 NGR risk factor for stroke. These data call for caution when treating with warfarin these individuals.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - October 1, 2017 Category: Cardiology Authors: Gentian Denas, Giacomo Zoppellaro, Seena Padayattil Jose, Emilia Antonucci, Francesco Marongiu, Daniela Poli, Sophie Testa, Armando Tripodi, Gualtiero Palareti, Vittorio Pengo Tags: Original Research Article Source Type: research

Gender ‐related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry
ConclusionsIn a contemporary “real‐life” cohort of patients with ACS treated with PCI and focusing on antiplatelet treatment 1‐year ischemic outcome does not differ by gender, while women do present more frequently not actionable bleeding events.
Source: Cardiovascular Therapeutics - July 14, 2017 Category: Cardiology Authors: Ioanna Xanthopoulou, Periklis Davlouros, Spyridon Deftereos, Michalis Hamilos, George Sitafidis, Ioannis Kanakakis, Manolis Vavouranakis, John Goudevenos, John Lekakis, Dimitrios Alexopoulos Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Effect of postprocedural full ‐dose infusion of bivalirudin on acute stent thrombosis in patients with ST‐elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real‐world population
ConclusionPost‐PCI full‐dose bivalirudin infusion is safe and has a trend to protect against acute ST in STEMI patients undergoing primary PCI in real‐world settings.
Source: Cardiovascular Therapeutics - May 12, 2017 Category: Cardiology Authors: Heyang Wang, Zhenyang Liang, Yi Li, Bin Li, Junming Liu, Xueyi Hong, Xin Lu, Jiansheng Wu, Wei Zhao, Qiang Liu, Jian An, Linfeng Li, Fanli Pu, Qiang Ming, Yaling Han Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Gender related differences in antiplatelet treatment patterns and outcome: insights from the GreekAntiPlatElet(GRAPE) Registry
ConclusionsIn a contemporary ‘real life’ cohort of ACS patients treated with PCI and focusing on antiplatelet treatment one‐year ischemic outcome does not differ by gender, while women do present more frequently not actionable bleeding events.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - April 1, 2017 Category: Cardiology Authors: I. Xanthopoulou, P. Davlouros, S. Deftereos, M. Hamilos, G. Sitafidis, I. Kanakakis, M. Vavouranakis, J. Goudevenos, J. Lekakis, D. Alexopoulos Tags: Original Research Article Source Type: research

The Tasmanian Atrial Fibrillation Study: Transition to Direct Oral Anticoagulants 2011 ‐2015
ConclusionsDOACs rapidly became the most commonly prescribed class of antithrombotic medications in patients with AF soon after they became widely available. Warfarin and antiplatelet prescribing declined significantly, although a substantial proportion of patients continued to be prescribed antiplatelet therapy. Patients who were initiated on DOACs were typically younger with fewer comorbid conditions compared to those initiated on warfarin therapy.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - January 31, 2017 Category: Cardiology Authors: Endalkachew Admassie Alamneh, Leanne Chalmers, Luke R. Bereznicki Tags: Original Research Article Source Type: research

Effect of Post ‐procedural Full Does Infusion of Bivalirudin on Acute Stent Thrombosis in Patients with ST‐elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes in a large real‐world population
ConclusionPost‐PCI full‐does bivalirudin infusion is safe and has a trend to protect against acute ST in STEMI patients undergoing primary PCI in real world settings.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - January 13, 2017 Category: Cardiology Authors: Heyang Wang, Zhenyang Liang, Yi Li, Bin Li, Junming Liu, Xueyi Hong, Xin Lu, Jiansheng Wu, Wei Zhao, Qiang Liu, Jian An, Linfeng Li, Fanli Pu, Qiang Ming, Yaling Han Tags: Original Research Article Source Type: research

Warfarin persistence among atrial fibrillation patients – why is treatment ended?
ConclusionsAlthough persistence to warfarin among AF patients proves higher than previously reported, there is room for improvement since half of the discontinuers have questionable reasons for treatment stop and the majority of them receive no other efficient stroke prophylaxis.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - August 26, 2016 Category: Cardiology Authors: Fredrik Bj örck, E k Agnes, Lars Johansson, Anders Själander Tags: Original Research Article Source Type: research

Clinical and Economic Outcomes among Elderly Myocardial Infarction Survivors in the United States
ConclusionsRisks of mortality and cardiovascular events remain high in a Medicare population surviving >1 year after a MI. Continuing healthcare costs are doubled over pre‐MI levels up to five years after an MI. Secondary prevention measures beyond the acute post‐MI period may be indicated to reduce risk and cost in this chronic disease phase.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - July 31, 2016 Category: Cardiology Authors: Erru Yang, Michael Stokes, Saga Johansson, Carl Mellstr öm, Elizabeth Magnuson, David J. Cohen, Phillip Hunt Tags: Original Research Article Source Type: research

Non‐vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights
ConclusionsFor the primary outcome, the absolute benefits of NOACs were modest (NNT/year values being large). Reduced hemorrhagic stroke rates with NOACs could be due to superior embolic infarct prevention and fewer consequential hemorrhagic transformations. Among apixaban recipients, the absolute mortality benefit exceeded that for the primary outcome, indicating prevention of additional unrelated deaths. The substantially greater NOAC acquisition costs need viewing against probable greater safety and the avoidance of monitoring bleeding risks.
Source: Cardiovascular Therapeutics - March 3, 2016 Category: Cardiology Authors: Cyrus R. Kumana, Bernard M.Y. Cheung, David C.W. Siu, Hung‐Fat Tse, Ian J. Lauder Tags: Unsolicited Review Source Type: research

Non Vitamin K Oral Anticoagulants versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments yield Novel Insights
ConclusionsFor the primary‐outcome, the absolute benefits of NOACs were modest (NNT/year values being large). Reduced haemorrhagic‐stroke rates with NOACs could be due to superior embolic infarct prevention and fewer consequential haemorrhagic transformations. Among apixaban recipients, the absolute mortality benefit exceeded that for the primary‐outcome, indicating prevention of additional unrelated deaths. The substantially greater NOAC acquisition costs need viewing against probable greater safety and the avoidance of monitoring bleeding risks.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - January 4, 2016 Category: Cardiology Authors: Cyrus R Kumana, Bernard M Y Cheung, David C W Siu, Hung‐Fat Tse, Ian J Lauder Tags: Unsolicited Review Source Type: research

The burden of major adverse cardiac events and antiplatelet prevention in patients with coronary or peripheral arterial disease
ConclusionDespite gaps in the literature, this assessment showed that MACE's risk is substantial among CAD or PAD patients and that the use of preventive therapies is suboptimal. Development of additional preventive therapies for these patients is warranted.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - December 1, 2015 Category: Cardiology Authors: Hanane Khoury, Louis Lavoie, Sharon Welner, Kerstin Folkerts Tags: Unsolicited Review Source Type: research

Optimal Duration of Dual Antiplatelet Therapy after Drug‐Eluting Stents: Meta‐Analysis of Randomized Trials
ConclusionDAPT continued beyond 6 months after second generation DES implantation decreases stent thrombosis and myocardial infarction, but increases major bleeding and all‐causes mortality compared to shorter DAPT (aspirin alone). There was no difference in cardiac mortality or stroke.
Source: Cardiovascular Therapeutics - September 11, 2015 Category: Cardiology Authors: Elsayed Abo‐salem, Said Alsidawi, Hina Jamali, Mohamed Effat, Tarek Helmy Tags: Original Research Article Source Type: research

Optimal duration of dual antiplatelet therapy after drug eluting stents: Meta‐analysis of randomized trials
ConclusionDAPT continued beyond 6 months after second generation DES implantation, decreases stent thrombosis and myocardial infarction, but increases major bleeding and all‐causes mortality compared to shorter DAPT (aspirin alone). There was no difference in cardiac mortality or stroke.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - May 25, 2015 Category: Cardiology Authors: Elsayed Abo‐salem, Said Alsidawi, Hina Jamali, Mohamed Effat, Tarek Helmy Tags: Original Research Article Source Type: research

Pages: 1  2